Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Nov 17, 2022

News

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Evaxion announced today promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

Benchmarking freely available HLA typing algorithms across varying genes, coverages and typing resolutions

Nov 16, 2022

Publications

Benchmarking freely available HLA typing algorithms across varying genes, coverages and typing resolutions

Nikolas Hallberg Thuesen, Michael Schantz Klausen, Shyam Gopalakrishnan, Thomas Trolle and Gabriel Renaud

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

Nov 14, 2022

News

Evaxion Announces Third Quarter 2022 Financial Results and Business Update

Evaxion announced today its third quarter 2022 financial results and provided an operational and business update

Evaxion CEO comments on strategic focus

Nov 10, 2022

News

Evaxion CEO comments on strategic focus

Evaxion today announced that it intends to further increase its focus on its lead oncology assets EVX-01 and EVX-02/03 to bring them to clinical proof of concept followed by out-licensing. The Company further plans preclinical partnering of its early-stage programs under its infectious disease platforms.

Evaxion welcomes Per Norlén as new CEO.

Oct 5, 2022

News

Evaxion welcomes Per Norlén as new CEO.

Evaxion announces that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 1st.

Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy

Sep 22, 2022

News

Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy

In the company’s first phase 2b clinical trial, Evaxion is evaluating the efficacy and safety of EVX-01 in adults with metastatic melanoma. The trial is being conducted globally at clinical sites across the US, Europe, and Australia in collaboration with Merck & Co., Inc., which is supplying the trial with its PD-1 inhibitor, KEYTRUDA®.

Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School

Sep 6, 2022

News

Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School

Evaxion announced that the Company, in collaboration with UMass Chan Medical School (“UMass Chan”), has received a grant from the U.S. National Institutes of Health (“NIH”) for the development of a gonorrhea lead vaccine candidate.

Investor and Friends event

Aug 31, 2022

Events

Investor and Friends event

Come meet us at our place in Hørsholm

Second Quarter 2022 Financial Results and Provides Business Update

Aug 10, 2022

News

Second Quarter 2022 Financial Results and Provides Business Update

Today Evaxion announced its second quarter 2022 financial results and provided an operational and business update.

Evaxion Biotech A/S Announces Executive Management Changes

Aug 2, 2022

News

Evaxion Biotech A/S Announces Executive Management Changes

Lars Staal Wegner has decided to resign as the Company’s Chief Executive Officer (CEO). Dr. Wegner will remain with the Company in an advisory role to the Company’s new CEO and Board of Directors.

Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

Jul 29, 2022

News

Evaxion Biotech to Host Q2 2022 Corporate Update Conference Call & Webcast on August 10

Evaxion will present its second-quarter 2022 financial results on August 10 at 8.30 a.m. EDT.

Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target

Jun 30, 2022

News

Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target

Evaxion has identified Gonorrhea as its second bacterial target for treatment with the Company’s EVX-B2 vaccine product candidate.

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.